{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:20:50Z","timestamp":1781659250649,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijid.2023.04.412","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:17:26Z","timestamp":1683307046000},"page":"53-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-1685","authenticated-orcid":false,"given":"Davide","family":"Marangoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1533-441X","authenticated-orcid":false,"given":"Roberta Maria","family":"Antonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-4037","authenticated-orcid":false,"given":"Marco","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Streva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Povolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Malentacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Zammarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Rossolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-7118","authenticated-orcid":false,"given":"Michele","family":"Spinicci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.04.412_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijid.2023.04.412_sbref0002","series-title":"Refusal of the marketing authorisation for Lagevrio (molnupiravir)","year":"2023"},{"key":"10.1016\/j.ijid.2023.04.412_bib0003","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/cid\/ciab538","article-title":"Chronic asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the immunocompromised patient: new challenges and urgent needs","volume":"74","author":"Lodi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.04.412_bib0004","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10875-022-01313-6","article-title":"Long-term SARS-CoV-2 asymptomatic carriage in an immunocompromised Host: Clinical, Immunological, and Virological Implications","volume":"42","author":"Spinicci","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.ijid.2023.04.412_bib0005","doi-asserted-by":"crossref","first-page":"e28430","DOI":"10.1002\/jmv.28430","article-title":"Coronavirus disease 2019 rebounds following nirmatrelvir\/ritonavir treatment","volume":"95","author":"Lai","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijid.2023.04.412_bib0006","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166485","article-title":"Combined molnupiravir-nirmatrelvir treatment improves effect on SARS-CoV-2 in Macaques","volume":"8","author":"Rosenke","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijid.2023.04.412_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijid.2023.04.412_bib0008","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/microorganisms10071475","article-title":"The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS-CoV-2 replication in vitro","volume":"10","author":"Gidari","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijid.2023.04.412_bib0009","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.ijid.2023.04.412_bib0010","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/cid\/ciac868","article-title":"Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell Acute Lymphoblastic Leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir","volume":"76","author":"Ford","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.04.412_bib0011","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/cid\/ciac847","article-title":"Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host","volume":"76","author":"Trottier","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.04.412_bib0012","article-title":"Case report: sotrovimab, remdesivir and nirmatrelvir\/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19","volume":"9","author":"Baldi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijid.2023.04.412_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113058","article-title":"Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro","volume":"150","author":"Jonsdottir","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ijid.2023.04.412_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1072202","article-title":"Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijid.2023.04.412_bib0015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s43440-022-00388-7","article-title":"Oral antiviral treatments for COVID-19: opportunities and challenges","volume":"74","author":"Rahmah","year":"2022","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.ijid.2023.04.412_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03331-22","article-title":"Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2","volume":"10","author":"Wagoner","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijid.2023.04.412_bib0017","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 Subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.04.412_bib0018","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2023.04.412_bib0019","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/dkac433","article-title":"Successful use of nirmatrelvir\/ritonavir in immunocompromised patients with persistent and\/or relapsing COVID-19","volume":"78","author":"Graziani","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223005465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223005465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:12:16Z","timestamp":1761120736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971223005465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":19,"alternative-id":["S1201971223005465"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.04.412","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.04.412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}